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The concept of adjuvants or adjuvant systems, used in vaccines, exploit evolutionary
relationships associated with how the immune system may initially respond to a foreign
antigen or pathogen, thus mimicking natural exposure. This is particularly relevant during
the non-specific innate stage of the immune response; as such, the quality of this
response may dictate specific adaptive responses and conferred memory/protection to
that specific antigen or pathogen. Therefore, adjuvants may optimise this response in the
most appropriate way for a specific disease. The most commonly used traditional
adjuvants are aluminium salts; however, a biodegradable adjuvant, MCT®, was
developed for application in the niche area of allergy immunotherapy (AIT), also in
combination with a TLR-4 adjuvant—Monophosphoryl Lipid A (MPL®)—producing the
first adjuvant system approach for AIT in the clinic. In the last decade, the use and
effectiveness of MCT® across a variety of disease models in the preclinical setting highlight
it as a promising platform for adjuvant systems, to help overcome the challenges of
modern vaccines. A consequence of bringing together, for the first time, a unified view of
MCT® mode-of-action from multiple experiments and adjuvant systems will help facilitate
future rational design of vaccines while shaping their success.
Keywords: adjuvants, virus-like particles, MicroCrystalline Tyrosine (MCT®), allergy, disease, immunization,
Monophosphoryl Lipid A (MPL®), vaccinesINTRODUCTION
The Evolution of Vaccines and Adjuvants
The concept of variolation (human inoculation/insertion of pathogens) dates back to the 10th
century in China, here, immunization against small pox used the live virus itself. Edward Jenner
practised variolation in the UK and moved the field to the next level in the last decade of the 18th
century by using a cowpox virus for immunization which eventually led to the first vaccine (derivedorg November 2020 | Volume 11 | Article 5949111
Heath et al. Adjuvant Systems Using MicroCrystalline Tyrosinefrom vaccinia virus from vacca, the Latin word for cow), and the
eradication of small pox in the 20th century (1–3). Again, during
the early 1900’s the pioneering work of Louis Pasteur, Alexandre
Yersin, and others was associated with the development of
attenuated and inactivated vaccines which progressed for a
variety of pathogens such as cholera, tetanus, polio,
tuberculosis, and a severe pneumonia-form of plague (Yersinia
pestis) (4–10).Fronti“Discoveries [made] by accidents and sagacity, of
things [the observers] were not in quest of” (1754,
quoted in Merton and Barber 2004, p. 2) (11).In the 1920’s, both Alexander Glenny and Gaston Ramon were
working with diphtheria toxins (12, 13). Production of bacterial
toxins became very efficient (14). It was not long before Glenny
referred to the use of a toxoid in humans for the first time in 1923
(13). Serendipity has led to some of the greatest discoveries and
breakthroughs in science and medicine over the past century.
Indeed, the story of adjuvants begins with a French veterinarian
who unlocked a secret weapon, at an intersection of chance and
wisdom. Gaston Ramon’s (1886–1963) crucial discovery, whilst at
the Pasteur Institute in Paris in the 1920’s, made the observation
that “local infection” (or abscesses at the injection site) was in some
way enhancing antibody (Ab) production (15). As such, a series of
experiments were set out and by adding a variety of substances (e.g.,
agar and starch oil) to an inoculation—substances he referred to as
adjuvants (from the Latin adiuvare, meaning to help or aid) -
resulted in enhanced tetanus and diphtheria anti-serum production
(15, 16). When Gaston Ramon discovered the immune potentiating
effect of such adjuvants, the human population was reeling from the
aftermath of the Spanish flu and faced burgeoning health risks from
pathogens. Moreover, vaccination against viruses, for example,
represented more of a challenge than vaccination against bacteria,
mostly because it was more difficult to grow them.
As part of Glenny’s work dealing with bacterial toxins, metal
salts (precipitates thereof) were employed during the purification
process, the adsorbed toxoid was subject to the wisdom of
Glenny to perform comparative immunological studies, which
indicated greatly enhanced immunological effects (14, 17),
illuminating the serendipitous points of discovery that have
shaped the modern world. Today, optimized versions of
“alum” salt precipitates [e.g., aluminium oxyhydroxide; AlO
(OH), aluminium phosphate; AlPO4)] have been the mainstay
of adjuvants in clinical vaccines for more than 70 years (16).
For most of this time, the scientific community considered the
principle or “dogma” of explaining the effectiveness of
aluminium adjuvants in the context of the “depot” effect -
immune stimulation through prolonged exposure of the
antigen (18, 19). However, more research devoted to this
question has revealed evidence that better explains adjuvancy
in the context of alums physicochemical attributes and biological
properties than a depot effect alone (20–26).
Tools to study the genome or cellular systems have developed
rapidly. This has inspired new strategies from empirical to
rational approaches to vaccine design and antigen carrier
(nano)-systems, for targeting both innate and adaptiveers in Immunology | www.frontiersin.org 2immune responses in tackling more challenging or emerging
diseases or improvements in safety and efficacy of others (27–
29). Vaccines are disruptive technologies and one of the most
cost-saving medical applications ever developed, and in the last
decades, their application in non-infectious diseases such as
allergy, cancer, diabetes, and even smoking cessation continue
to be developed (30–34).
While recombinant vaccines have generally improved safety
profiles compared with live-attenuated and whole-pathogen
vaccines, they are also often less immunogenic due to the
removal of their inherent pathogenic features and patterns.
Modern vaccine development focusses on bridging or
substituting this gap in order to improve their effectiveness
without compromising safety. As a consequence, the
development of new and sophisticated rational technologies
such as antigen (nano)-carrier systems [e.g., virus-like particles
(VLPs)] or combination of adjuvants (adjuvant systems) are
being employed to help overcome these challenges (29, 35).
Adjuvant Systems
Adjuvant Systems may comprise of a variety of classical
adjuvants or immunomodulators that are combined and
tailored for the specific antigen and target application. The
immune system has evolved to recognise repetitive surface
features like pathogen-associated molecular patterns (PAMPs),
which forms the basic principles in how they are able to activate
the innate immune system, which, in turn, leads to orchestration
of a specific adaptive response.
The benefits of vaccines and immunization against
pathogenic threats demonstrate a convincing positive benefit-
risk ratio over many decades, with the scope to eradicate disease.
The existing and evolving threats have been brought to light
recently with the spread of SARS-Cov-2, which some have
described as natures wake-up call to complacent civilisation;
threatening our era of peak globalisation, which has grown under
a safety net of medical and scientific advances. The consideration
of adjuvants in new vaccine development can be the difference to
what makes a vaccine effective or not. Particularly, so where
pathogens with more complex life cycles with intracellular habits
or pathogens with genetic variability exist. Optimizing vaccines
for this purpose has been historically slow and cumbersome (e.g.,
influenza, HIV, and malaria) and often requires a more robust
adaptive response. For billions of years, microbes have evolved in
this way, and this complexity has only just begun to be better
understood by scientists.
Immunology, Immunization, and
Immunotherapy
The innate and adaptive responses cover two broad phases of the
body’s response to a pathogen or vaccine. Pattern recognition
receptors (PRRs) on innate and adaptive immune cells [i.e.,
macrophages, dendritic cells (DCs), monocytes, neutrophils,
and B cells] have evolved to recognise conserved features that
are typical of pathogenic surface patterns [pathogen-associated
molecular patterns (PAMPs)], thus being able to signal an
incoming agent as a threat, that is distinguishable from “self”
(16, 36, 37). PRRs will trigger intracellular signaling cascades,November 2020 | Volume 11 | Article 594911
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early inflammatory response to infection or immunization is
diverse and tightly regulated, its early orchestration shaping the
quality in adaptive immunity. A key mediator in shaping the
quality of this adaptive response are antigen-presenting cells
(such as DCs, macrophages, and B cells), particularly where
vaccines are concerned (16).
How effectively a pathogen is removed will depend on the
interplay between the innate and adaptive response and the quality
that sits behind this immune reaction. In essence, the immune
response to infection involves innate immune activation and
antigen-specific responses of B and T cells, with the ideal vaccine
typically able to induce Th1/Th17 immune responses that can direct
this toward inactivation and removal of the threat, followed by
development of immune memory (Figure 1) (16).
Allergy or parasitic infections are somewhat distinct, inducing
strong type-2 immune responses. While Th2/IgE responses
control parasitic infections, robust response to parasitic
infections is also associated with allergic phenomena (38).
Type 1 allergy is mediated by specific IgE, which results in an
exaggerated immune response against an otherwise harmless
substance. However, growing evidence of a negative association
between parasitic infections and allergy at an ecological level
highlights the complex inter-relationship between the two (39).
Allergic disease is considered a new epidemic of the 21st century,
a burgeoning disease particularly in urban areas (40). The most
effective way to treat IgE-mediated allergies is through allergen-
specific immunotherapy (AIT), which entails repeated
administration of specific allergens to patients resulting in
protection against the allergic and inflammatory reactions (41).
Despite its success, subcutaneous immunotherapy is generally
slow and cumbersome for the patient. However, the advances in
vaccinology may be exploited here too with the advent of newFrontiers in Immunology | www.frontiersin.org 3antigen nano-carriers, modified ways in presenting the allergen
and next-generation adjuvants that may advance treatment for
chronic diseases and emerging/re-emerging diseases into the
modern world (42).
Tailoring Adjuvant Systems
The combination of adjuvants (adjuvant systems) have been
pioneered for the last few decades and has resulted in significant
advancements in vaccine design and treatments. However, only
few alternative adjuvants (other than alum) have been approved
for human use (Table 1).
Antigen carrier systems such as VLPs can be engineered to
optimise antigen presentation and harbour intrinsic adjuvanticity,
as these can be packaged with immunomodulators/adjuvants or
combined with depot adjuvants to further tailor and optimise the
immune response appropriately (29, 30, 50). The most commonly
used traditional adjuvants are aluminium salts; however, for
decades, a biodegradable adjuvant based on the crystalline form
of the non-essential amino acid L-Tyrosine, MCT®, has been
utilized in the niche area of allergy immunotherapy (43, 45). It is
only in the last decade that its use and effectiveness across a variety
of challenging disease models in the preclinical setting highlights it
as a promising platform for adjuvant systems to help overcome the
challenges associated with modern vaccines and challenging
diseases (29).
The application of MCT® as an adjuvant has more recently
been extended across a broader vaccine scope with and without
VLP antigen carrier systems; one such VLP system uses the
cucumber mosaic VLP (CuMVTT), which includes intrinsic
adjuvant features such as an engineered universal T helper cell
epitope (CD4+, based on the tetanus toxin) and encapsulated
RNA (TLR7/8 agonists) (51). The disease challenge models
which have screened MCT® -adjuvanted vaccines consist ofFIGURE 1 | Innate and adaptive immunity time course. The non-specific early inflammatory response is characterized by cells of the innate immune system (e.g.,
Macrophages) which will recognise conserved repetitive features from bacteria or viruses. If recognized as a threat, the adaptive immune responses develops with
the activation of lymphocytes.November 2020 | Volume 11 | Article 594911
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one Ferret model (H1N1 Influenza) (50, 52–54). It is important
to note that the proof of concept disease models capture
biomarker measurements indicative of protection (efficacy)
compared to control groups, with performance of the vaccine
assessed against groups formulated with alum. Extended
pharmacokinetic experiments featured in the Melanoma model
(VLP-MCT®)provides unique insights into the importance of
the depot effect of MCT® when combined with nanoparticles in
orchestrating a robust adaptive cytotoxic T cell response (50).MCT® AND MONOPHOSPHORYL LIPID-A
IN ALLERGY IMMUNOTHERAPY
MCT® is a biodegradable depot adjuvant developed primarily for
use in short-course subcutaneous allergy immunotherapy (AIT),
in combination with native allergens or modified allergens
(allergoids) with or without Monophosphoryl Lipid A®
(MPL®, a Toll-like receptor 4 agonist) (48). Allergoid MCT®-
MPL® formulations are referred to as Pollinex Quattro®. Clinical
evidence for the use of allergoid-MCT®-MPL® adjuvant systems
in allergy immunotherapy is well documented (55, 56).
Combining an allergoid with an adjuvant system pays tribute
to the short-course posology of the vaccine, which is
administered in four to six injections within a year pre-
seasonally, as opposed to longer-treatment courses (>30
injections) that are commonly applied in AIT and which are
typically combined with alum depots (57).
The most recent phase II studies (including the optimal dose
levels planned for Phase III) have recently been published for a
six-injection presentation of Pollinex Quattro (PQ) Birch and
PQ Grass (49, 55). These products are subject to further clinicalFrontiers in Immunology | www.frontiersin.org 4development, and a phase III trial for both PQ Birch and PQ
Grass are currently planned. Furthermore, a combined
transcriptomic and proteomic biomarker analysis is pending in
a phase III study for PQ Grass, while a smaller preliminary data
set is available from an earlier trial, establishing some initial
hypotheses related to mode-of-action/predictive efficacy
biomarkers (46). Furthermore, Pollinex Quattro is listed in the
current European Academy of Allergy and Clinical Immunology
(EAACI) AIT guidelines with grade IA recommendation (56).
The PQ products employing the MCT® and MPL® adjuvant
system are designed to desensitise allergic individuals by
modulating the inherent Th1/Th2 imbalance of atopic disease.
The mechanism involved in MCT® -MPL® adjuvancy has not
been fully elucidated, but the synergistic attenuation of IgG may
prolong protective immunity, which is a further benefited by
combining the two adjuvants. The added benefit of MPL® has
been demonstrated in the clinic too (58). Several possible
mechanisms might account for Toll-like receptor 4 (TLR-4)
mediated effects in atopy and asthma. For instance, signaling
through the TLRs is generally associated with production of Th1
cytokines by DCs via IL-12, leading to increased IFN-g
production (59).
For the PQ product portfolio, in total, 26 Phase I-III clinical
trials have been conducted using various allergoids, with
different formulations and dosing posologies, including 4695
patients in total (Table 2).
The combination of MCT® and MPL® has been shown to be
safe and well tolerated in these Phase I-III studies and based on
post-marketing data, i.e., >150,000 individuals have received PQ
treatment (2004–2019) and an estimated >450,000 treatment
courses have been dispensed (Data on file, Allergy Therapeutics
plc). Moreover, the safety of MPL® has been demonstrated in
several products using MPL® as an adjuvant (60). MPL® is
currently used as an adjuvant in the licensed product CervarixTABLE 1 | Adjuvants used in licensed vaccines and immunotherapy [adapted from Di Pasquale et al. (16)].
Adjuvant Composition Immunomodulation Product Indications
Aluminium (alum) Aluminium salts mixed with antigens
aluminium oxyhydroxide; AlO(OH),
aluminium phosphate; AlPO4
Th2-biased, prolonged immune exposure (DC uptake),
DAMP, Inflammasome activation, potent innate/Ab and
inflammatory responses
Diphtheria, tetanus, pertussis,
poliomyelitis, hepatitis A, hepatitis B,
meningococcal, pneumococcal
Virosomes Phospholipid membrane (either a mono-
or bi-layer) vesicle incorporating virus
derived proteins
Target antigen-presenting cells (APCs) and B cells Hepatitis and influenza
AS03/
Oil-in-water/
MF59
Squalene-based Increase antigen uptake by APCs, Ab B cell responses, Influenza pandemic and seasonal.
AS04 • Aluminium salt; AlO(OH)
• 3-deacyl-monophosphoryl lipid A
Increase antigen uptake by APCs, TLR-4 agonist, Th1 –
biased Ab responses
Hepatitis B and Human Papillomavirus
AS01 Liposome-based
• 3-deacyl-monophosphoryl lipid A
• Purified saponin; QS-21
Th1-immunity
Early innate inflammasome activation,
Antigen-specific CD4+ T cells in addition to antigen-specific
Abs, robust IFN-g response.
Recombinant zoster vaccine (Shingrix,
RZV).
Mosquirix (Plasmodium falciparum; RTS,
S’).
Montanide ISA51 Mineral oil Increase antigen uptake by APCs, Ab B cell responses Non-small cell lung cancer
MCT® Crystalline form of L-Tyrosine
(MicroCrystalline Tyrosine); MCT®
Biodegradable depot (43, 44), Th1-biased, Increase antigen
uptake by APCs, highly immunogenic B and T cell responses
(45).
Pollinex® short-course allergy
immunotherapy.
MCT®-MPL® Crystalline form of L-Tyrosine
(MicroCrystalline Tyrosine); MCT®
3-deacyl-monophosphoryl lipid A
Th1-biased, Increase antigen uptake by APCs, highly
immunogenic B and T cell responses. TLR-4 agonist, Th1 –
biased Ab responses (46, 47),
Pollinex Quattro® short-course allergy
immunotherapy (48, 49).November 2020 | Volume 11 | Article 594911
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and Shingrix [herpes zoster (shingles)] (60). Since first being
licensed in 2006, over 200 million doses of HPV vaccines have
been distributed globally, no significant safety issues have been
observed (WHO, 2016).
In relation to MCT®, 1575 patients have received MCT® alone
as placebo group in placebo controlled GCP studies (including 9
million injections of all MCT® platforms) (Data on file, Allergy
Therapeutics plc). MCT® as an adjuvant alone has been shown to
be safe and well tolerated, without any treatment related serious
adverse events (SAEs) being reported and no relevant effects
observed in safety laboratory and vital signs. In a recent position
paper, authored by an independent taskforce of EAACI members, a
review of adjuvants and formulations currently used in marketed
allergy immunotherapies discussed, stating, “Since its introduction
into AIT in 1970, there are no specific safety concerns known for
MCT®. It can be anticipated that this fully biodegradable adjuvant
will also in future studies not reveal side effects” (61).MCT® MODE OF ACTION
In depth comparative adjuvant studies are, in general, limited in
number, which may in part be due to the proprietary nature of
investigational adjuvants. Since alum is the adjuvant of choice
and most broadly studied, it is a useful comparator to use when
studying vaccine mode-of-action.
MCT® and alum have been compared head-to-head in a
number of preclinical mouse models. In one such study, MCT®
combined with Ovalbumin stimulated striking and comparable B
cell responses (antigen-specific IgG1, IgG2a, IgG2b, and IgG3)
(45). The relevant induction of IgE was of interest, since IgE
antibodies (Abs) are the key mediator of the allergic response
and an “unwanted” reaction. Here, MCT® triggered less IgE
production than alum. This is an observation that has been
consistently described in other studies, highlighting a key benefit
in using a Th1-biased depot adjuvant in AIT and its reported
synergy when combined with MPL® as an adjuvant system (45,
52–54). The specific T cell (CD4+) cytokine response may, in
part, explain this since MCT® induced a more Th1-biased
response. Of note, IL-4 is required for the Ig switch to IgE, and
the lower propensity to induce IL-4, compared to alum, supports
this notion (45). Both Alum and MCT® were found to activate
the inflammasome but this activation was not essential for the
stimulation of B and T cell responses, nor early inflammatory
markers (i.e., eosinophils and neutrophils) which were induced
by MCT® and alum adjuvants, when assessed by peritoneal
lavage (45). Similar results have been reported for alum in miceFrontiers in Immunology | www.frontiersin.org 5deficient in IL-1R or NLRP3 (26, 62). Hence, although alum and
MCT® may activate the inflammasome in vitro, this does not
affect the adaptive immune response needed for Ab production
in AIT. Furthermore, increased B and T cell responses induced
with alum or MCT® -based vaccines did not depend on signaling
through toll-like receptors, which is distinct from the TLR
agonist MPL® (45).
MCT® ‘s half-life at the injection site was modelled in
preclinical models, with an estimated half-life of 48 hours (44).
MCT® has a broad adsorption capacity with model allergens and
carriers such as VLPs (63). The depot effect has been
characterized with VLP nanoparticles, and this prolonged
immune exposure was attributed to play an important role in
priming T cells and, in particular, stimulating cytotoxic T cells—
a response in which other adjuvants struggle to confer (50).
Shardlow and Exley have further characterized the
physicochemical properties of MCT®, which describes needle-like
crystalline structures, some of which stack together, to produce a
high degree of structural order (64). The resultant crystals combined
to form extensive rod-like features the majority of which exceeded
10 µm in length under physiological conditions (median size ca. 21
µm). MCT® also appeared to lack a water decomposition phase by
Thermogravimetric analysis, which indicated the lack of physically
adsorbed moisture at the surface interface. A decrease in hydroxyl
display/surface functionality has been associated with the reduced
reactivity of aluminium salts in vitro in terms of proinflammatory
cytokine production, reactive oxygen species (ROS) generation and
inflammasome activation. The size of MCT® may influence its
recognition and uptake by THP-1 macrophages in vitro (64). In
general, adjuvant particles between 1 and 3 µm in size have been
considered optimal for recognition and engulfment bymacrophages
(65). The large hydrodynamic length of MCT® crystals in biological
medium (>ca. 10 µm) appeared to partially stymie the scavenging
capacity of THP-1 macrophages in vitro (64). This may contribute
to the safety profile ofMCT®, since limitedmacrophage uptakemay
prohibit transport via barriers such as blood-brain and rapid
transport to lymph nodes. The lower propensity to induce IgE/
Th2-polarized responses and early inflammatory responses
compared to alum, as described in Leuthard et al., 2018, may be
partly attributed to the size and distribution of larger and more
ordered crystalline structures of L-Tyrosine (45). This is in stark
contrast to results obtained using a crystalline aluminium adjuvant
where its optimal particle size (median size, 1.4 µm) appeared to
more readily facilitate cytoplasmic loading (64).
Both adjuvants were characterized by immediate infiltration
of neutrophils and eosinophils (MCT® to a lesser degree) (45).
This was the only study, to our knowledge, to characterize such
inflammatory responses for MCT®. Although many innate
reactions are important for the onset of adaptive immunity,
the role of inflammasome activation in immunization and AIT
has not been precisely defined. Indeed, MCT® harbors different
physicochemical properties, such as particle size, morphology,
adsorption characteristics, and local pharmacokinetics compared
to alum, which undoubtedly plays a pivotal role in shaping the
quality of the Th1/Th2 biological response. MCT®’s roles in the
innate and adaptive response are outlined in Figure 2.TABLE 2 | Overview of clinical studies performed with Pollinex Quattro (PQ)
products (Data on file, Allergy Therapeutics Plc).
Phase I Phase II Phase III Total
PQ Ragweed 1 3 1 5
PQ Grass 4 8 1 13
PQ Tree 1 3 1 5
PQ Birch 0 2 1 3November 2020 | Volume 11 | Article 594911
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The physical association ofMPL® forMCT® has been characterized
using fluorescently labeled LPS (Lipopolysaccharide) as a substitute
for MPL® (Figure 2). The LPS was labeled with fluorescein
isothiocyanate (FITC). Through confocal microscopy, it was
possible to see that the labelled LPS is associated with the MCT®
depot. Furthermore, in Bell et al., 2015 allergoid and MPL®
adsorption to MCT® in PQ allergy AIT formulations was
determined in vitro using specific allergen IgE allergenicity and
MPL® content methods (63). The predominant mode (i.e., force)
of adsorption between MPL® and MCT® was investigated by
competition inhibitor binding experiments. This was
predominantly inferred as C–H⋯p interactions between the 2-
deoxy-2-aminoglucose backbone on MPL® and aromatic ring of
L-tyrosine in MCT® (63) (Figure 3B). Furthermore, the physical
association ofMPL® across the needle-like crystalline structure of 20Frontiers in Immunology | www.frontiersin.org 6mg/mlMCT®has been characterized usingfluorescently labeledLPS
as a substitute for MPL® via confocal microscopy (Figure 3A).
Immunological synergy has been documented in allergoid
formulations with or without MPL®, highlighting a synergistic
relationship in IgG induction (47, 58). Formulation science is
often an overlooked or under-appreciated discipline and often
adjuvants may be included into formulations without having an
extended level of characterisation of their interactions and
compatibility with active substances and/or other adjuvants.
Indeed, adsorption characteristics of adjuvants may shape bio-
availability and in turn vaccine effectiveness (ratio of free versus
adjuvants bound antigen may determine antigen draining
kinetics) (28). MCT® demonstrates consistent adsorption
characteristics, when combined with antigens and allergoids
(63). As such, quality attributes may be controlled for over the
course of the products shelf life and investigated in preclinicalA
B C
FIGURE 2 | An overview of the immune response after vaccination with an MCT® depot. (A) The early innate response is characterized by immediate exudation of
neutrophils and eosinophils in vivo. The role of inflammasome/DAMP-associated mechanisms have not been precisely defined. The innate response has recorded an
increase in dendritic cells (DCs), observed 24 h post-injection (45). MCT® is biodegradable/biocompatible with an estimated half-life of 48 h at the injection site (44).
As a result, it is cleared within 7 days with a return to a local steady state. The biodegradable depot properties of MCT® are thought to be key in orchestrating the
subsequent adaptive response. (B) The infiltrating antigen presenting cells to the draining lymph node, induce sustained and robust B cell response, via MHC class II
antigen presentation (45, 52–44, 54), with sustained IgG antibody titers. The prolonged immune exposure of antigen is thought to further DC uptake and initiate CD4
T helper cell (Tfh) clonal expansion and differentiation (45). Furthermore, immune complexes may form with follicular dendritic cells (FDCs) via Fcg receptors (Cd16
and CD32) and complement receptors (CD35). (C) The depot properties of MCT® have been shown to be key in generating a more robust cytotoxic T cell response,
thus the priming of T cells combined with optimal antigen delivery, such as when combined with VLPs, are key drivers in orchestrating this arm of the adaptive
response (50).November 2020 | Volume 11 | Article 594911
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optimise properties of vaccines.
MCT® Combined With Poorly
Immunogenic Antigens
It is important to note that the combination of MCT® with
poorly immunogenic antigens such as Ovalbumin (45), CSP (53),
and H1N1 (54) produce consistent results in generating a robust
B cell response and protective efficacy in preclinical models.
MCT® was found to possess high protein-binding capacity
(adsorption compatibility with the antigens) (54, 63). In the
influenza study, a close correlation of haemagglutination
inhibition and neutralization titres in groups formulated with
MCT® or alum suggests that the two adjuvants were inducing
functionally equivalent influenza-specific Abs. Leuthard et al.,
2018 using Ovalbumin, highlighted similar findings (45).
However, key differences related to MCT®’s physicochemical
properties (particulate structure), depot function and biased Th1
specificity highlights some key distinctions of the platform that
should be considered when assessing other adjuvants toFrontiers in Immunology | www.frontiersin.org 7combined, tailor and optimise the immune response
appropriately for specific disease applications.MCT® IN VIRUS-LIKE PARTICLE
FORMULATIONS: HELPING OVERCOME
THE CHALLENGES OF MODERN
VACCINES
VLPs can be engineered a specific way to modulate the immune
response. In pathogen-specific prophylactic applications, they
have proven to be well tolerated and highly immunogenic. The
21st century sees further advancements of the technology
harnessing state-of-the-art techniques in leveraging the
platform to tackle complex diseases. Mohsen et al., 2020 pay
tribute to these advancements in the context of the design,
delivery and draining dynamics of VLPs (29) and their
respective stages of clinical development and success (30).
Table 3 summarizes immunological mechanisms of VLP-basedA
B
FIGURE 3 | (A) The physical association of MPL® across the needle-like crystalline structure of 20 mg/ml MCT® has been characterized using fluorescently labeled
LPS (100 µg; Lipopolysaccharide) as a substitute for MPL® via confocal microscopy. (B) Proposed C–H⋯p interactions between the 2-deoxy-2-aminoglucose on
MPL® and the aromatic ring on L-tyrosine, based on inhibitor studies with Naphthalene (Adapted from Bell et al., 2015).November 2020 | Volume 11 | Article 594911
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an adjuvant system.
In regards to targeting B cells and Abs, a major factor here
relates to the size and ability of VLPs to display antigens in
optimal fashion [repetitive antigen display, Pathogen Associated
Structural Patterns (PASPs)], resulting in very robust induction
in Ab responses. In an elegant study by Link and colleagues, 2012
the importance of size and repetitive structure as critical factors
for efficient Ag presentation to B cells was demonstrated. In this
case, IgM Abs which VLPs are recognized by, recruit the
complement component C1q followed by activation of C3,
resulting in persistent deposition of antigen on follicular
dendritic cells (FDCs) via complement receptor CD35 (29, 69).
Furthermore, the physical association of a repetitive antigen
display distanced by 5–10 nm permit optimal B cell receptor
crosslinking. The size of VLPs (20–200 nm) enable efficient fast
and transient trafficking of native antigen to the lymph nodes
highlighting pharmacokinetic advantages of the platform and
their ability to target APCs to orchestrate a robust adaptive
response (66).
Vaccines targeting pathogens that are more complex will need to
induce both B and effector T cells, which is where adjuvant design
may come into playmore deeply. If our understanding related to the
mode-of-action of depot adjuvants/immunomodulators, continue
to grow and become more well established, effective rational
approaches in VLP vaccine design may be taken in tailoring
dynamic responses of desired specificity.
Adjuvants physically associated with VLPs (e.g., TLR ligands)
may enhance B cell responses. Prokaryotic RNA is known to be
more effective and superior in this regard and, most importantly,
is the ability of this adjuvant-effect to help differentiate a memory
B cell pool into secondary plasma cells, which produce very high
levels of Abs. This may allow for more efficient and rapid control
of an evolving pathogen (67, 70, 71). The CuMVTT VLP is an
example of this, based on an ssRNA plant virus, engineered to
harbour a universal T cell epitope derived from the tetanus
toxoid, to optimise T cell help for B cells (51). The CuMVTT
encapsulates pRNA, which acts as a TLR 7/8 ligand. This
particular platform has been remarkably effective in generating
proof of concept data in different veterinary vaccines for insect-
bite hypersensitivity in horses (IL-5), atopic dermatitis in dogs
(IL-31), and preclinical PoC in allergy (peanut and cat), pain in
osteoarthritis (NGF), Zika virus infection (ED-III), psoriasis (IL-
17a), and malaria (PvTRAP and PvCSP) (51–53, 72–78).Frontiers in Immunology | www.frontiersin.org 8CuMVTT in a Peanut Allergy Model
Where allergic disease is concerned, VLPs have achieved
preclinical proof of concept and are subject to further clinical
development, notably for peanut allergy (32, 74). Here, targeting
B cells using CuMVTT combined with a single major allergen, was
able to protect against a complex peanut extract in a murine
anaphylaxis model (74). In this study mice were immunized with
one of three vaccines containing either a mixture of allergens
found in whole extract of roasted peanut or with just one single,
purified peanut allergen (“Ara h 1” or “Ara h 2”). Regardless of
which vaccine was used, immunization strongly reduced
systemic and local allergic symptoms in vaccinated subjects
and protected against anaphylaxis upon subsequent challenge
with a whole peanut allergen mixture. The fact that one injection
against a single allergen was sufficient to induce protection
against a whole peanut allergen mixture has never been
described before and could be applied in different relevant
allergies. In addition, the vaccine proved hypoallergenic as
previously described (79), which in peanut allergy is a vital
characteristic to avoid anaphylactic reactions upon dosing and
to improve patient uptake.CuMVTT-MCT® in a Malaria Disease Model
The inclusion of the depot adjuvant MCT® has highlighted the
effectiveness of prolonged physical release of VLP nanoparticles,
which have been shown to be particularly effective at priming
effector T cell responses. In a number of different comparative
adjuvant studies in disease challenge models for Malaria (P. vivax)
and Cancer (Melanoma), a step-wise improvement in biomarkers/
disease progression, with the addition of MCT®, has been
consistently demonstrated (50, 52, 53). In these studies, the
CuMVTT VLPs was screened in a comparative adjuvant study
with alum. Table 4 summarizes the findings from a comparative
adjuvant study using CuMVTT in the Malaria disease model, which
highlights the effectiveness in combining nanoparticles with MCT®
as an optimal way to formulate VLP-vaccines, taking advantage of
the physiological properties of the lymphatic system.
In this study, the vaccine efficacy in the malaria survival
challenge models were significantly improved if the vaccines
were formulated with MCT®, compared to alum. This was
explained, in part, due to the high and sustained Ab titres
induced in a step-wise improvement by adding MCT®
(compared to non-adjuvanted groups) which indicated a moreTABLE 3 | Immunological mechanisms of VLP-based vaccines complement other adjuvants like MCT® and may provide added benefit (29, 43, 45, 47–66–68).
VLP scaffold MCT®
Repetitive and native antigen display - optimal BCR-crosslinking (PAMP; Pathogen Associated Molecular Pattern) Local inflammation (early innate responses)
Complement activation Inflammasome activation
Recognition by natural Abs and other innate humoral factors DC activation
Particulate for APC targeting
B cell activation
T cell activation
Fast – transient migration to draining lymph nodes Depot – prolong immune-exposure
Co-delivered adjuvant (e.g., TLR-ligands)November 2020 | Volume 11 | Article 594911
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indicated by the IgG subset data (see Table 4).
CuMVTT-MCT® in a Cancer (melanoma)
Model
Combining CuMVTTTT- VLPs displaying T cell epitopes with
MCT® as an adjuvant has been tested in an aggressive
transplanted melanoma murine model B16F10. The results
showed improved anti-tumor efficacy when formulating the
nano-vaccine with the micro-sized adjuvant MCT® (Figure 4).
This hybrid system facilitated an optimal delivery of the vaccine
to efficiently prime the adaptive immune system. Furthermore,
the MCT® adjuvant was as potent as B type CpGs in a direct
comparative assessment of efficacy. These findings highlight the
translational potential for application for any solid tumor.Frontiers in Immunology | www.frontiersin.org 9CONCLUSIONS
• MCT® is the crystalline formulation of the non-essential
amino acid L-Tyrosine, biodegradable, with an estimated
half-life of 48 h at the site of injection (44, 80).
• Formulated as a depot for controlled release from injection
site - immunomodulation with allergens, antigens, whole
cells, polysaccharides, and lipids.
• Characterized adsorption capacity and stability (broad vaccine
scope) facilitating Th1-specific immunological augmentation.
• MCT® and Alum [AlO(OH)] are both distinct crystalline
depot adjuvant formulations and induced broadly
comparable B- and T-cell responses in mice (45).
• MCT® induced less Th2 polarisation than Alum (less IL-4
and IgE). A higher ratio of IgG/IgE (i.e., relatively higherFIGURE 4 | Confocal microscopy imaging of fluorescent dye AF488 CuMVTT-p33 nano-vaccine following formulation with the MCT® (20 mg/ml) adjuvant.TABLE 4 | Summary of vaccine efficacy with MCT® and Alum –depot adjuvants. The respective studies conjugated CuMVTT with TRAP or a CSP antigen from P. vivax
(independent of CuMVTT). Formulations were compared against vaccines formulated with Alum.
Protection against Plasmodium berghei/vivax
Formulations screened Humoral response Cellular response (CD8+ T cells) Vaccine efficacy in survival challenge Reference
CMVtt-PvTRAP + MCT® ** (PvTRAP + MCT®)
IgG2b > IgG2a > IgG1
** (PvTRAP + MCT®) *** (PvTRAP + MCT®) (52)
CSP + MCT®
** (CSP + MCT®)
IgG2a > IgG2b > IgG1
N.D
* (CSP + MCT®)
(53)November 2020 | Volume 11 | Article 59491***p = 0.0001 **p = 0.001; *p = 0.01 (one week after second boost); N.D; not determined.1
Heath et al. Adjuvant Systems Using MicroCrystalline TyrosineIgG to IgE) which has been reported to be a surrogate marker
indicative of efficacy of AIT in humans (81).
• MCT® facilitates induction of CD8 T-cell responses (45, 50).
• AIT with MCT® adjuvanted allergens induce protection in a
mouse model of anaphylaxis (45) and is formulated (adsorbed)
withMPL®asanadjuvant systemtoprovide short-courseAIT in
humans.
• MCT® induces IL-1b secretion in vitro, but inflammasome
activation does not affect B- and T-cell responses in vivo (45).
• MCT® acts independent of TLR activation (45).
• The combination of MCT® with poorly immunogenic antigens
such as Ovalbumin (45), CSP (53) and H1N1 (54) produce
consistent results in generating a robust B cell response and
protective efficacy in preclinical challenge models.
• The adsorption of MCT with CuMVTT virus-like-particles
demonstrates significant added benefit in enhancing
immunological (B and T cells) responses in Malaria and
Cancer (Melanoma) preclinical disease models (50, 52).Frontiers in Immunology | www.frontiersin.org 10AUTHOR CONTRIBUTIONS
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